IPCA Laboratories saw the highest growth of 2.99% in patent filings in May and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.24% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of IPCA Laboratories‘s patent filings and grants. Buy the databook here.
IPCA Laboratories has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 33% of filings. The South Korea(KR), United States(US), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where IPCA Laboratories is filings its patents. Among the top granted patent authorities, IPCA Laboratories has 100% of its grants in United States(US).
Immatics and Roche could be the strongest competitors for IPCA Laboratories
Patents related to rare diseases and climate change lead IPCA Laboratories's portfolio
IPCA Laboratories has the highest number of patents in rare diseases followed by, climate change. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Petrochemicals related patents lead IPCA Laboratories portfolio followed by ovarian cancer, and pancreatic cancer
IPCA Laboratories has highest number of patents in petrochemicals followed by ovarian cancer, pancreatic cancer, severe acute respiratory syndrome (sars), and lymphoma.
For comprehensive analysis of IPCA Laboratories's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.